Commentary: Oncologic drugs in patients with organ dysfunction: a summary.
There are few prospective data regarding the pharmacokinetics and clinical toxicity of commonly used chemotherapeutics in cancer patients with organ dysfunction. Although increasing numbers of studies are investigating newer chemotherapeutics in patients with liver or kidney dysfunction, most guidelines for dosing, especially for established agents, remain empiric. This review describes the available data (both prospective and case study) evaluating the impact of renal and hepatic dysfunction on toxicity and dosing of commonly used chemotherapeutics and provides a practical summary for their use in this setting.
Superfin
Diana
D
University of California Davis Cancer Center, 4501 X Street, Sacramento, California 95817, USA.
Iannucci
Andrea A
AA
Davies
Angela M
AM
D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D016022:Case-Control Studies; D006801:Humans; D007668:Kidney / Q000187:drug effects; D007674:Kidney Diseases / Q000503:physiopathology*; D008099:Liver / Q000187:drug effects; D008107:Liver Diseases / Q000503:physiopathology*; D011446:Prospective Studies; D059003:Topoisomerase Inhibitors
D000903:Antibiotics, Antineoplastic; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D059003:Topoisomerase Inhibitors